New insights into the role of COX 2 in inflammation

被引:103
作者
Gilroy, DW
Colville-Nash, PR
机构
[1] Univ Texas, Houston Med Sch, Vasc Biol Res Ctr, Houston, TX 77030 USA
[2] Univ Texas, Houston Med Sch, Div Hematol, Houston, TX 77030 USA
[3] Univ London St Bartholomews Hosp Med Coll, Dept Expt Pathol, London EC1M 6BQ, England
[4] Royal London Sch Med & Dent, London EC1M 6BQ, England
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2000年 / 78卷 / 03期
关键词
cyclo-oxygenase; nonsteroidal anti-inflammatory drugs; inflammation; peroxisome proliferator-activated receptor; cyclopentenone prostaglandins; stress proteins;
D O I
10.1007/s001090000094
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cyclo-oxygenase (COX) is responsible for the synthesis of bioactive prostanoids, the inhibition of which serves as the basis for the mode of action of clinically used nonsteroidal anti-inflammatory drugs. While there were suggestions as early as the 1970s that an inducible isoform of COX exists, it was only in the early 1990s that COX 2 was identified, cloned and sequenced. Not surprisingly, this new isoform was expressed at sites of inflammation and reported to contribute to the inflammatory response. Recently, however, evidence is emerging to suggest that COX 2 also has anti-inflammatory properties. In this review, the two faces of COX 2 are examined, with emphasis on its role in regulating inflammatory resolution, including possible mechanisms of action.
引用
收藏
页码:121 / 129
页数:9
相关论文
共 88 条
  • [1] Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
    Anderson, GD
    Hauser, SD
    McGarity, KL
    Bremer, ME
    Isakson, PC
    Gregory, SA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) : 2672 - 2679
  • [2] STRUCTURE OF THE HUMAN CYCLO-OXYGENASE-2 GENE
    APPLEBY, SB
    RISTIMAKI, A
    NEILSON, K
    NARKO, K
    HLA, T
    [J]. BIOCHEMICAL JOURNAL, 1994, 302 : 723 - 727
  • [3] DISTRIBUTION OF CYCLOOXYGENASE ISOFORMS IN MURINE CHRONIC GRANULOMATOUS INFLAMMATION - IMPLICATIONS FOR FUTURE ANTIINFLAMMATORY THERAPY
    APPLETON, I
    TOMLINSON, A
    MITCHELL, JA
    WILLOUGHBY, DA
    [J]. JOURNAL OF PATHOLOGY, 1995, 176 (04) : 413 - 420
  • [4] NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND LIFE THREATENING COMPLICATIONS OF PEPTIC-ULCERATION
    ARMSTRONG, CP
    BLOWER, AL
    [J]. GUT, 1987, 28 (05) : 527 - 532
  • [5] PURIFICATION, CHARACTERIZATION AND SELECTIVE-INHIBITION OF HUMAN PROSTAGLANDIN-G/H SYNTHASE-1 AND SYNTHASE-2 EXPRESSED IN THE BACULOVIRUS SYSTEM
    BARNETT, J
    CHOW, J
    IVES, D
    CHIOU, M
    MACKENZIE, R
    OSEN, E
    NGUYEN, B
    TSING, S
    BACH, C
    FREIRE, J
    CHAN, H
    SIGAL, E
    RAMESHA, C
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1209 (01): : 130 - 139
  • [6] Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2
    Bishop-Bailey, D
    Hla, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) : 17042 - 17048
  • [7] Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development
    Braissant, O
    Wahli, W
    [J]. ENDOCRINOLOGY, 1998, 139 (06) : 2748 - 2754
  • [8] CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531
  • [9] Colville-Nash PR, 1998, J IMMUNOL, V161, P978
  • [10] Growth factors in angiogenesis: Current interest and therapeutic potential
    ColvilleNash, PR
    Willoughby, DA
    [J]. MOLECULAR MEDICINE TODAY, 1997, 3 (01): : 14 - 23